

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/FFF75E3CBA9EEN.html>

Date: December 2022

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: FFF75E3CBA9EEN

Abstracts

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Drugs In Development, 2022, provides an overview of the Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) pipeline landscape.

Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle tissue and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside that constrains movement. Symptoms swellings in fibrous tissue, pain, fever, muscle ossification and restricted movement of joints. Treatment includes surgery and medications to help relieve symptoms of FOP, such as pain and inflammation.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under

development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 4, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Overview

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Therapeutics

Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Therapeutics

Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Companies

Involved in Therapeutics Development

AstraZeneca Plc

Clementia Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Incyte Corp

Ipsen SA

La Jolla Pharmaceutical Company

Pfizer Inc

Regeneron Pharmaceuticals Inc

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Drug Profiles

dipyridamole - Drug Profile

Product Description

Mechanism Of Action

DS-6016 - Drug Profile

Product Description

Mechanism Of Action

garetosmab - Drug Profile

Product Description

Mechanism Of Action

INCB-00928 - Drug Profile

Product Description

Mechanism Of Action

IPN-60130 - Drug Profile

Product Description

Mechanism Of Action

palovarotene - Drug Profile

Product Description

Mechanism Of Action

saracatinib difumarate - Drug Profile

Product Description

Mechanism Of Action

sirolimus - Drug Profile

Product Description

Mechanism Of Action

Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile

Product Description

Mechanism Of Action

Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Fibrodysplasia Ossificans Progressiva - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile

Product Description

Mechanism Of Action

trevogrumab - Drug Profile

Product Description

Mechanism Of Action

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Dormant Projects

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Discontinued Products

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Product Development Milestones

Featured News & Press Releases

Oct 25, 2022: Ipsen statement on updated timeline for palovarotene FDA Advisory

Committee meeting

Jun 29, 2022: Ipsen announces U.S. FDA priority review for palovarotene new drug application in patients with fibrodysplasia ossificans progressiva following resubmission

Jan 24, 2022: Health Canada approves Ipsen's Sohonos (palovarotene capsules) as the first approved treatment for Fibrodysplasia Ossificans Progressiva

Aug 13, 2021: Ipsen announces withdrawal of palovarotene NDA, confirming intention to re-submit following additional data analyses

May 28, 2021: Ipsen confirms U.S. FDA accepts new drug application for Palovarotene as the first potential treatment worldwide for fibrodysplasia ossificans progressiva (FOP)

Oct 30, 2020: Regeneron provides update on the Garetosmab phase 2 LUMINA-1 trial in fibrodysplasia ossificans progressiva (FOP)

Sep 10, 2020: Ipsen to present new Insights at ASBMR for potential treatment of ultra-rare disease Fibrodysplasia Ossificans Progressiva (FOP), including global phase III MOVE Trial results

Aug 25, 2020: Ipsen to present results from MOVE, the first global phase III trial in fibrodysplasia ossificans progressiva (FOP), at ASBMR 2020 annual meeting

Mar 27, 2020: Ipsen to restart dosing of palovarotene in FOP studies

Jan 27, 2020: Ipsen temporarily stops palovarotene dosing in FOP trials

Jan 10, 2020: Regeneron reports positive data from rare bone disease trials

Jan 09, 2020: Regeneron announces encouraging garetosmab phase 2 results in patients with ultra-rare debilitating bone disease

Dec 09, 2019: Ipsen initiates partial clinical hold for palovarotene IND120181 and IND135403 studies

Mar 27, 2019: Blueprint Medicines provides update on clinical progress of BLU-782

Feb 11, 2019: Clementia granted Rare Pediatric Disease Designation by FDA for Palovarotene for Fibrodysplasia Ossificans Progressiva

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by AstraZeneca Plc, 2022

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Clementia Pharmaceuticals Inc, 2022

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Daiichi Sankyo Co Ltd, 2022

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Incyte Corp, 2022

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Ipsen SA, 2022

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by La Jolla Pharmaceutical Company, 2022

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Pfizer Inc, 2022

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Regeneron Pharmaceuticals Inc, 2022

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Dormant Projects, 2022

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/FFF75E3CBA9EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/FFF75E3CBA9EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970